Systematic review of 10 studies (8 meta-analysed; 1409 patients) of drug-resistant Pseudomonas aeruginosa infection: 30-day mortality did not significantly differ with ceftazidime-avibactam vs ceftolozane-tazobactam (OR 0.93); no other outcome differed.
Meta-analysisn = 1,409
Almangour et al. Ceftazidime-avibactam versus ceftolozane-tazobactam in the treatment of drug-resistant Pseudomonas aeruginosa: a meta-analysis